• CCG-1423: Unraveling RhoA Inhibitor Utility Beyond Oncology

  2025-10-19

  Explore how CCG-1423, a potent RhoA inhibitor, advances cancer research and reveals new frontiers in tight junction biology and viral pathogenesis. This in-depth analysis provides unique mechanistic insights and application strategies for RhoA/ROCK pathway modulation.

• ZCL278: Advanced Insights into Cdc42 Inhibition for Disea...

  2025-10-18

  Explore how ZCL278, a selective Cdc42 inhibitor, empowers next-generation research into cell motility suppression, neuronal branching inhibition, and fibrotic disease modeling. This article delivers a deep mechanistic analysis and strategic differentiation from prior content.

• SR-202: Selective PPARγ Antagonist for Immunometabolic Re...

  2025-10-17

  SR-202 redefines metabolic and immunological research with precise, selective PPARγ antagonism, enabling advanced dissection of adipocyte differentiation and macrophage polarization. Its unique properties accelerate anti-obesity, insulin resistance, and type 2 diabetes studies by offering robust, reproducible inhibition of the PPAR signaling pathway.

558 records 38/38 page Previous First page 上5页 363738